Retatrutide and Ipamorelin
No clinical trial has studied this combination. Ipamorelin is not approved for human use. Retatrutide is not FDA approved. All rationale for combining them is anecdotal.
This page reviews what is known about combining retatrutide with ipamorelin: the regulatory status of each compound, what human evidence exists, theoretical rationale discussed in online communities, and the risks that are known or plausible.
What Each Compound Is
Why People Search for This Combination
Peptide communities discuss ipamorelin with retatrutide for lean mass support during fat loss. Ipamorelin is considered a selective GH secretagogue with purportedly fewer side effects than other GH-releasing peptides. The combination is discussed as a way to stimulate GH release while using retatrutide for fat loss. All rationale is anecdotal.
Human Evidence
No published clinical trial has studied retatrutide combined with ipamorelin. Ipamorelin has limited human pharmacokinetic data but no approved indication. Retatrutide's Phase 2 trial showed up to 24.2% mean weight loss at 48 weeks. No body composition data exists for the combination.
Theoretical Rationale
The theoretical rationale is that ipamorelin's GH secretagogue effects could support lean mass preservation during retatrutide-induced caloric restriction. GH has known effects on body composition including fat mobilization and lean mass support. Whether ipamorelin's GH stimulation would be clinically meaningful in this context is unknown and unstudied.
Known and Plausible Risks
- Retatrutide: GI adverse events, heart rate increase, gallbladder effects, class-level precautions for thyroid C-cell tumors and pancreatitis
- Ipamorelin: Water retention, potential effects on cortisol and prolactin; long-term safety unknown
- Combined: Unknown interaction risks; no safety data for the combination exists; ipamorelin is not approved for human use
Body Composition Considerations
Retatrutide's Phase 2 data showed significant fat mass reduction with some lean mass loss. Ipamorelin's effects on body composition in humans are not well established. No body composition data exists for the combination.
What People Are Discussing Online
Reddit communities (r/Peptides, r/PeptideScience) discuss ipamorelin with retatrutide as a lean-mass-preserving stack. Common claims include reduced lean mass loss during aggressive fat loss and improved recovery. These claims are anecdotal. Ipamorelin is frequently discussed alongside CJC-1295 as a combined GH secretagogue protocol.
Regulatory and Legal Context
Ipamorelin is not approved for human use. It is sold as a research chemical. Use of unapproved peptides carries unknown safety risks. Retatrutide is not FDA approved. Using two unapproved compounds simultaneously outside a supervised clinical context carries significant legal and medical risks.
Frequently Asked Questions
No. No published clinical trial has studied this combination. Ipamorelin is not approved for human use. No safety or efficacy data exists for the combination.
Ipamorelin is not approved for human use. It is sold as a research chemical. Use of unapproved peptides carries unknown safety risks.
Online communities discuss this combination for lean mass support during fat loss. The rationale is anecdotal and not supported by clinical evidence.
Ready to Start Your Physician Review?
$477 one-time payment. No membership. No recurring billing. No charge unless approved.
START PHYSICIAN REVIEW